Drugs / Dovramilast
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04139226 | Aug 2019 → Feb 2020 | — | Amgen | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT07172659 | Sep 2026 → Jan 2027 expected | erythema nodosum | Medicines Development for Global Health | Recruiting | No outcome recorded |
| Phase 2 | NCT03807362 | Jan 2018 → Mar 2021 | erythema nodosum, leprosy | The Leprosy Mission Nepal | Unknown | No outcome recorded |
| Phase 2 | NCT02968927 | Nov 2016 → Sep 2018 | tuberculosis | The Aurum Institute NPC | Unknown | No outcome recorded |
| Phase 2 | NCT01300208 | Oct 2010 → Jan 2013 | cutaneous lupus erythematosus | Amgen | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02652546 Comparator | Jan 2016 → May 2017 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2025-04-30 | Medicines Development for Global Health | Regulatory Medicines Development for Global Health receives U.S. FDA clearance of Investigational New Drug Application for dovramilast in leprosy type 2 reaction medicinesdevelopment.com ↗ |
| 2025-02-20 | Medicines Development for Global Health | Regulatory Medicines Development for Global Health submits an Investigational New Drug Application for dovramilast for the treatment of leprosy type 2 reaction medicinesdevelopment.com ↗ |
| 2023-11-03 | Medicines Development for Global Health | Regulatory Medicines Development for Global Health Receives FDA Orphan Drug Designation for Dovramilast to Treat Leprosy Type 2 Reaction medicinesdevelopment.com ↗
Medicines Development for Global Health announced today that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to dovramilast for the treatment of leprosy type 2 reaction. |
All press releases naming this drug 5 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dovramilast | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07172659 ↗ |
| Known as | CC-11050 | “CC-11050 is a novel anti-inflammatory compound with potential to treat a variety of chronic inflammatory conditions and cytokine storms associated with infectious diseases.” NCT02652546 ↗ |
| Action | Inhibit | “CC-11050 is a selective phosphodiesterase-4 inhibitor (PDE4)” NCT02652546 ↗ |
| Modality | Small molecule | — CHEMBL4297460 ↗ |
| Route | Oral | “take capsules” NCT02652546 ↗ |